Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of positive psychological intervention on psychosocial adjustment in childbearing-age patients with breast cancer.

Frontiers in oncology·2026

Same author

Hybridized Local and Charge-Transfer Emitter With a Dual-Hindered Indoline Donor for Fast and Efficient Red Plastic Scintillators.

Angewandte Chemie (International ed. in English)·2026

Same author

Loss of UFL1 drives chromosome instability and tumorigenesis of prostate cancer.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

NRIP1 co-activates nuclear translocated FOXO3 to upregulate TFAM expression and promote radioresistance in non-small cell lung cancer.

Cell death discovery·2026

Same author

Radiotherapy combined with immunotherapy achieves clinical complete response in elderly metastatic penile cancer: a case report.

Frontiers in immunology·2026

Same author

Clinical practice guidelines for the preservation and repair of severed limbs.

Chinese medical journal·2026

Search research articles

Related Experiment Video

Updated: May 27, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Lipid Metabolic Rewiring During Continuous Prostate Cancer Progression Defines a Biologically Relevant Four-Gene

Rongna Li¹, Hongying He¹, Hui Sun¹

¹Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, 519000, China.

Biological Procedures Online

|May 26, 2026

Summary

This study identifies continuously dysregulated lipid metabolism genes in prostate cancer progression. A four-gene signature (ALDH3A2, ENO2, PPP1CB, PTGIS) effectively predicts patient survival and risk, highlighting lipid metabolism

Keywords:

Biomarker Lipid metabolism Prognosis Progression Prostate cancer

More Related Videos

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Experiment Videos

Last Updated: May 27, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Area of Science:

Oncology
Metabolic Research
Genetics

Background:

Lipid metabolic reprogramming is crucial in prostate cancer progression.
Genes continuously dysregulated from normal to metastatic prostate cancer are not fully understood.
Their biological and prognostic significance requires further investigation.

Purpose of the Study:

Identify lipid metabolism genes linked to continuous prostate cancer progression.
Develop a prognostic signature for stratifying patient survival.

Main Methods:

Utilized clinical prostate cancer specimens and an in vivo RM-1 tumor model.
Analyzed transcriptomic data (GSE6919) to find shared genes across progression stages.
Applied LASSO regression to TCGA data for prognostic model construction.
Validated core genes and assessed biological relevance through functional assays and immune infiltration analysis.

Main Results:

Identified 44 continuously dysregulated lipid metabolism genes.
Established a four-gene prognostic signature (ALDH3A2, ENO2, PPP1CB, PTGIS) that stratified patients by survival.
The signature correlated with clinical T stage, Gleason score, and immune infiltration patterns.
Functional assays revealed context-dependent roles of core genes in lipid metabolism.

Conclusions:

Identified continuously dysregulated lipid metabolism genes in prostate cancer.
Developed a four-gene prognostic signature for survival prediction and risk assessment.
Highlights lipid metabolic rewiring in prostate cancer evolution and offers potential biomarkers.